keyword
MENU ▼
Read by QxMD icon Read
search

Gynecologic oncology group

keyword
https://www.readbyqxmd.com/read/28341300/a-phase-i-pharmacokinetic-study-of-intraperitoneal-bortezomib-and-carboplatin-in-patients-with-persistent-or-recurrent-ovarian-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#1
Danielle A Jandial, William E Brady, Stephen B Howell, Heather A Lankes, Russell J Schilder, Jan H Beumer, Susan M Christner, Sandra Strychor, Matthew A Powell, Andrea R Hagemann, Kathleen N Moore, Joan L Walker, Paul A DiSilvestro, Linda R Duska, Paula M Fracasso, Don S Dizon
PURPOSE: Intraperitoneal (IP) therapy improves survival compared to intravenous (IV) treatment for women with newly diagnosed, optimally cytoreduced, ovarian cancer. However, the role of IP therapy in recurrent disease is unknown. Preclinical data demonstrated IP administration of the proteasome inhibitor, bortezomib prior to IP carboplatin increased tumor platinum accumulation resulting in synergistic cytotoxicity. We conducted this phase I trial of IP bortezomib and carboplatin in women with recurrent disease...
March 21, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28338493/surgery-for-recurrent-uterine-cancer-surgical-outcomes-and-implications-for-survival-a-case-series
#2
Lavinia Domenici, Katherine Nixon, Flavia Sorbi, Maria Kyrgiou, Joseph Yazbek, Marcia Hall, Jeremy Campbell, Norma Gibbons, Won-Ho Edward Park, Hani Gabra, Christina Fotopoulou
OBJECTIVE: The purpose of this study was to describe the patterns of relapse in uterine cancer (UC) and the role of surgery in the recurrent setting. METHODS: We describe surgical and clinical outcomes of all patients who underwent surgery for recurrent UC in a gynecological oncology tertiary referral center between May 1, 2013, and April 30, 2016. Progression-free survival and overall survival were estimated using Kaplan-Meier methods with the surgery at relapse being the starting point...
March 23, 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28334914/clinical-utility-of-a-self-administered-questionnaire-for-assessment-of-hereditary-gynecologic-cancer
#3
Kenta Masuda, Akira Hirasawa, Haruko Irie-Kunitomi, Tomoko Akahane, Arisa Ueki, Yusuke Kobayashi, Wataru Yamagami, Hiroyuki Nomura, Fumio Kataoka, Eiichiro Tominaga, Kouji Banno, Nobuyuki Susumu, Daisuke Aoki
Background: A patient's medical history and familial cancer history are important information for assessing the risk of hereditary cancer. We have generated a self-administered questionnaire for patients with gynecologic cancer. This pilot study analyzed the usefulness of this questionnaire and the rates of patients that meet the Society of Gynecologic Oncology criteria in ovarian cancer and endometrial cancer patients. Method: Ovarian or endometrial cancer patients were recruited for this study...
December 23, 2017: Japanese Journal of Clinical Oncology
https://www.readbyqxmd.com/read/28327944/a-phase-2-randomized-double-blind-placebo-%C3%A2-controlled-study-of-chemo-immunotherapy-combination-using-motolimod-with-pegylated-liposomal-doxorubicin-in-recurrent-or-persistent-ovarian-cancer-a-gynecologic-oncology-group-partners-study
#4
B J Monk, M F Brady, C Aghajanian, H A Lankes, T Rizack, J Leach, J M Fowler, R Higgins, P Hanjani, M Morgan, R Edwards, W Bradley, T Kolevska, P Foukas, E Swisher, K S Anderson, R Gottardo, J K Bryan, M Newkirk, K L Manjarrez, R S Mannel, R M Hershberg, G Coukos
Background: A phase 2, randomized, placebo-controlled trial was conducted in women with recurrent epithelial ovarian carcinoma to evaluate the efficacy and safety of motolimod-a Toll-like receptor 8 (TLR8) agonist that stimulates robust innate immune responses-combined with pegylated liposomal doxorubicin (PLD), a chemotherapeutic that induces immunogenic cell death. Patients and methods: Women with ovarian, fallopian tube, or primary peritoneal carcinoma were randomized 1 : 1 to receive PLD in combination with blinded motolimod or placebo...
February 21, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28324920/an-open-label-randomized-parallel-phase-ii-trial-to-evaluate-the-efficacy-and-safety-of-a-cremophor-free-polymeric-micelle-formulation-of-paclitaxel-as-first-line-treatment-for-ovarian-cancer-a-korean-gynecologic-oncology-group-study-kgog-3021
#5
Shin-Wha Lee, Yong-Man Kim, Chi Heum Cho, Young Tae Kim, Seok Mo Kim, Soo Young Hur, Jae-Hoon Kim, Byoung-Gie Kim, Seung-Cheol Kim, Hee-Sug Ryu, Soon Beom Kang
Purpose: Genexol-PM is a biodegradable cremophor EL-free polymeric micelle formulation of paclitaxel. Here we compared efficacy and safety of Genexol-PM plus carboplatin vs. Genexol plus carboplatin for ovarian cancer treatment. Materials and Methods: In this multicenter, randomized, phase II study, patients with FIGO IC-IV epithelial ovarian cancer were randomly assigned (1:1) to receive Genexol-PM 260 mg/m2 or Genexol 175 mg/m2 with 5 AUC carboplatin every three weeks (6 cycles)...
March 21, 2017: Cancer Research and Treatment: Official Journal of Korean Cancer Association
https://www.readbyqxmd.com/read/28314589/fgfr2-mutations-are-associated-with-poor-outcomes-in-endometrioid-endometrial-cancer-an-nrg-oncology-gynecologic-oncology-group-study
#6
Yvette W Jeske, Shamshad Ali, Sara A Byron, Feng Gao, Robert S Mannel, Rahel G Ghebre, Paul A DiSilvestro, Shashikant B Lele, Michael L Pearl, Amy P Schmidt, Heather A Lankes, Nilsa C Ramirez, Golnar Rasty, Matthew Powell, Paul J Goodfellow, Pamela M Pollock
PURPOSE: Activating FGFR2 mutations have been identified in ~10% of endometrioid endometrial cancers (ECs). We have previously reported that mutations in FGFR2 are associated with shorter disease free survival (DFS) in stage I/II EC patients. Here we sought to validate the prognostic importance of FGFR2 mutations in a large, multi-institutional patient cohort. METHODS: Tumors were collected as part of the GOG 210 clinical trial "Molecular Staging of Endometrial Cancer" where samples underwent rigorous pathological review and had more than three years of detailed clinical follow-up...
March 14, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28303492/contributions-of-the-japanese-gynecologic-oncology-group-jgog-in-improving-the-quality-of-life-in-women-with-gynecological-malignancies
#7
REVIEW
Masayuki Futagami, Yoshihito Yokoyama, Muneaki Shimada, Shinya Sato, Etsuko Miyagi, Akiko Tozawa-Ono, Nao Suzuki, Masaki Fujimura, Yoichi Aoki, Satoru Sagae, Toru Sugiyama
The Japanese Gynecologic Oncology Group (JGOG) is leading Japan in the treatment of gynecological malignancies. The JGOG consists of three treatment committees focusing on uterine cervical cancer, endometrial cancer, and ovarian cancer. Each committee makes efforts to improve treatment and diagnosis. In addition, the Supportive and Palliative Care Committee was established in 2015. Novel studies of supportive care and palliative care have been initiated by this committee. Furthermore, surveys about not only treatment results such as overall survival rates but also quality of life (QOL) and cost-effectiveness assessments are performed by the ovarian cancer committee...
April 2017: Current Oncology Reports
https://www.readbyqxmd.com/read/28293723/continuous-wound-infiltration-system-for-postoperative-pain-management-in-gynecologic-oncology-patients
#8
Banghyun Lee, Kidong Kim, Soyeon Ahn, Hyun-Jung Shin, Dong Hoon Suh, Jae Hong No, Yong Beom Kim
PURPOSE: Major open surgery for gynecologic cancer usually involves a long midline skin incision and induces severe postoperative surgical site pain (POSP) that may not be effectively controlled with the conventional management. We investigated whether combining a continuous wound infiltration system (CWIS, ON-Q PainBuster(®)) and intravenous patient-controlled analgesia (IV PCA) effectively decreases POSP, compared with IV PCA alone, in gynecologic oncology patients. METHODS: This retrospective study included 62 Korean patients who received a long midline skin incision during gynecologic cancer surgery...
March 14, 2017: Archives of Gynecology and Obstetrics
https://www.readbyqxmd.com/read/28285845/a-stratified-randomized-double-blind-phase-ii-trial-of-celecoxib-for-treating-patients-with-cervical-intraepithelial-neoplasia-the-potential-predictive-value-of-vegf-serum-levels-an-nrg-oncology-gynecologic-oncology-group-study
#9
Janet S Rader, Michael W Sill, Jan H Beumer, Heather A Lankes, Doris Mangiaracina Benbrook, Francisco Garcia, Connie Trimble, J Tate Thigpen, Richard Lieberman, Rosemary E Zuna, Charles A Leath, Nick M Spirtos, John Byron, Premal H Thaker, Shashikant Lele, David Alberts
PURPOSE: To examine the effect of celecoxib on cervical intraepithelial neoplasia 3 (CIN 3). This is a NRG Oncology/Gynecologic Oncology Group study with translational biomarkers. PATIENTS AND METHODS: Patients with CIN 3 were randomized to celecoxib 400mg once daily (67 patients) or placebo (63 patients) for 14-18weeks. The primary outcome measure was histologic regression. A test of equal probabilities of success between two therapies was conducted, using Fisher's Exact Test at alpha=10% and 90% power when the treatment arm boosted the probability of success by 30%...
March 9, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28285537/milestone-clinical-trials-of-the-national-surgical-adjuvant-breast-and-bowel-project-nsabp
#10
REVIEW
Priya Rastogi, D Lawrence Wickerham, Charles E Geyer, Eleftherios P Mamounas, Thomas B Julian, Norman Wolmark
The National Surgical Adjuvant Breast and Bowel Project (NSABP) has made significant contributions in reducing the extent of breast surgery and in improving outcomes of patients with early-stage breast cancer through the conduct of large randomized clinical trials evaluating local and systemic therapy. In 2014, the NSABP merged with two other US National Cancer Institute-funded cooperative groups, the Radiation Therapy Oncology Group (RTOG) and the Gynecologic Oncology Group (GOG), to form NRG Oncology. The combined organization has 218 member institutions with more than 600 affiliate centers located throughout the United States, Canada, Puerto Rico, and other international sites...
February 2017: Chinese Clinical Oncology
https://www.readbyqxmd.com/read/28196674/cost-effectiveness-analysis-of-dose-dense-versus-standard-intravenous-chemotherapy-for-ovarian-cancer-an-economic-analysis-of-results-from-the-gynecologic-oncology-group-protocol-262-randomized-controlled-trial
#11
Brandon-Luke L Seagle, Shohreh Shahabi
OBJECTIVES: To determine the cost-effectiveness of dose-dense versus standard intravenous adjuvant chemotherapy for ovarian cancer using results from the no-bevacizumab cohort of the Gynecologic Oncology Group protocol 262 (GOG-262) randomized controlled trial, which reported a smaller absolute progression-free survival (PFS) benefit than the prior Japanese trial. METHODS: A three-state Markov decision model from a healthcare system perspective with a 21day cycle length and 28month time-horizon was used to calculate incremental cost-effectiveness ratio (ICER) values per progression-free life-year saved (PFLYS) using results from GOG-262...
February 10, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28190981/the-role-of-intraperitoneal-carboplatin-as-consalidation-chemotherapy-in-women-with-ovarian-carcinoma-report-of-our-experience-and-systematic-review
#12
Azamsadat Mousavi, Mojgan Karimi-Zarchi, Nadere Behtash, Mitra Modares-Gilani, Mahnaz Mokhtari-Gorgani, Nili Mehrdad, Mitra Rouhi, Pouria Yazdian Anari
BACKGROUND: Epithelial ovarian cancer is the leading cause of death from gynecology malignancy. The aim of this study was to assess the role of intraperitoneal chemotherapy with carboplatin, as a consolidative treatment, in reducing relapse and increasing survival of patients in advanced epithelial ovarian cancers, as well as evaluation of its toxicity. METHODS: This clinical trial was conducted on 30 patients with epithelial ovarian cancer in stages II-IV in Gynecology oncology department in Valiasr University Hospital, Tehran during 2005-2010...
December 2016: International Journal of Biomedical Science: IJBS
https://www.readbyqxmd.com/read/28190649/factors-associated-with-deciding-between-risk-reducing-salpingo-oophorectomy-and-ovarian-cancer-screening-among-high-risk-women-enrolled-in-gog-0199-an-nrg-oncology-gynecologic-oncology-group-study
#13
Phuong L Mai, Marion Piedmonte, Paul K Han, Richard P Moser, Joan L Walker, Gustavo Rodriguez, John Boggess, Thomas J Rutherford, Oliver Zivanovic, David E Cohn, J Tate Thigpen, Robert M Wenham, Michael L Friedlander, Chad A Hamilton, Jamie Bakkum-Gamez, Alexander B Olawaiye, Martee L Hensley, Mark H Greene, Helen Q Huang, Lari Wenzel
OBJECTIVES: Women at increased genetic risk of ovarian cancer (OC) are recommended to have risk-reducing salpingo-oophorectomy (RRSO) after completion of reproductive planning. Effective screening has not been established, and novel screening modalities are being evaluated. METHODS: Participants chose either RRSO or a novel OC screening regimen (OCS) as their risk management option, and provided demographic and other data on BRCA mutation status, cancer worry, perceived intervention risks/benefits, perceived cancer risk, and quality-of-life at enrollment...
April 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28187091/a-new-scoring-tool-to-assess-overall-survival-in-patients-with-intracerebral-metastases-from-gynecological-cancers
#14
Dirk Rades, Stefan Janssen, Amira Bajrovic, Theo Veninga, Dorothea Fischer, Steven E Schild
OBJECTIVE: This study aimed to facilitate individualized treatment strategies for intracerebral metastases from gynecological cancers by creating a specific overall survival (OS) score. METHODS/MATERIALS: Fifty-six patients irradiated for cerebral metastases from gynecological cancers were included. Eleven factors were retrospectively analyzed for OS: age, Eastern Cooperative Oncology Group (ECOG) performance score, cancer type, histology, histologic grading, initial stage, number of lesions, extracerebral metastases, time between cancer diagnosis and brain metastases treatment, recursive partitioning analysis class, and type of treatment...
March 2017: International Journal of Gynecological Cancer
https://www.readbyqxmd.com/read/28173966/nutrition-interventions-in-patients-with-gynecological-cancers-requiring-surgery
#15
REVIEW
Andreas Obermair, Marko Simunovic, Liz Isenring, Monika Janda
OBJECTIVE: Including developing countries, between 20 and 88% of gynecological oncology patients may present with at least mild malnutrition at diagnosis. Significant morbidity and mortality is attributed to malnutrition. Here we reviewed randomized clinical trials of nutritional interventions used to achieve early return to oral diet, enhance recovery from surgery and reduce adverse events in gynecological cancer patients undergoing surgery. METHODS: Ebscohost (CINAHL+Medline+PsycINFO), Cochrane, Embase, PubMed and Scopus databases were searched for articles published from 2000 onwards...
February 4, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28156639/determining-priority-symptoms-of-women-with-recurrent-ovarian-cancers-a-gynecologic-oncology-group-study
#16
Lari B Wenzel, Sandra Ward, Susan M Sereika, Robert P Edwards, Michael Spring, Catherine M Bender, Richard T Penson, Teresa Hagan
101 Background: The purpose of this study is to recommend a core set of priority symptoms to be assessed in research and clinical settings for women with recurrent ovarian cancers. METHODS: We used baseline data of 497 women with recurrent ovarian, fallopian, or primary peritoneal cancer participating in a symptom management randomized clinical trial (GOG-0259) to identify a core index of patient-reported priority symptoms. We used the Symptom Representation Questionnaire to assess priority rankings of 28 symptoms based on four criteria: (1) symptom prevalence, (2) patient-reported symptom severity, (3) percentage of women identifying each symptom as one of top three symptoms "I would like to get better control over", and (4) the association between symptom severity and functional wellbeing as measured by the Functional Assessment of Cancer Therapy - Ovarian...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28156596/impact-of-support-group-participation-in-women-with-gynecologic-cancer
#17
Adam Pyrzak, Fengjiao Hu, Ramses F Sadek, Donna Wheatley, Bunja Jane Rungruang, Sharad A Ghamande
252 Background: Unlike breast cancer support group literature, there is no data in women with gynecologic cancer who have different perspectives about their disease and therapy. We have a well-established, grass root level support group unique to women with gynecologic cancers that meets monthly. Our goal was to investigate perceived benefits of support group participation. METHODS: We developed an original questionnaire to evaluate the CSRA Gynecologic Oncology Support Group (CGOSG) participant's perceived effects of attending the group on their side effects and disease status which was distributed to patients attending CGOSG meetings...
October 9, 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152913/moving-towards-hospital-and-radiation-oncology-emr-integration-results-of-an-institutional-survey
#18
Murat Surucu, Barbara Kaczmarz, Teresita McCoo, John Roeske, William Small
152 Background: We are working to electronically integrate our radiation oncology EMR and our hospital EMR to improve communication and facilitate patient care. To guide integration, we surveyed providers and support staff at our academic cancer center to identify the important encounters/documents and how well these are currently communicated. METHODS: We sent an email survey to 182 MDs, nurses, and administrative staff at our cancer center. Respondents identified their role in the patient care team, and rated how important several radiation oncology-specific encounters/documents from "not important at all" to "extremely important" and rated the accessibility of these encounters/documents from "not at all accessible" to "exceptionally accessible...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28143870/early-detection-of-ovarian-cancer-using-the-risk-of-ovarian-cancer-algorithm-with-frequent-ca125-testing-in-women-at-increased-familial-risk-combined-results-from-two-screening-trials
#19
Steven J Skates, Mark H Greene, Saundra S Buys, Phuong L Mai, Powel H Brown, Marion Piedmonte, Gustavo C Rodriguez, John O Schorge, Mark Sherman, Mary B Daly, Thomas J Rutherford, Wendy R Brewster, David M O'Malley, Edward E Partridge, John Boggess, Charles W Drescher, Claudine Isaacs, Andrew Berchuck, Susan M Domchek, Susan A Davidson, Robert P Edwards, Steven A Elg, Katie Wakeley, Kelly-Anne Phillips, Deborah K Armstrong, Ira R Horowitz, Carol J Fabian, Joan Walker, Patrick M Sluss, William R Welch, Lori Minasian, Nora Horick, Carol H Kasten, Susan Nayfield, David S Alberts, Dianne M Finkelstein, Karen Lu
PURPOSE: Women at familial/genetic ovarian cancer risk often undergo screening despite unproven efficacy. Research suggests each woman has her own CA125 baseline; significant increases above this level may identify cancers earlier than standard 6-12 monthly CA125>35U/mL. EXPERIMENTAL DESIGN: Data from prospective Cancer Genetics Network and Gynecologic Oncology Group trials, which screened 3,692 women (13,080 woman-screening years) with a strong breast/ovarian cancer family history or BRCA1/2 mutations, were combined to assess a novel screening strategy...
January 31, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28114237/robotic-and-advanced-laparoscopic-surgical-training-in-european-gynecological-oncology-trainees
#20
Carmen Gan, Michaela Bossart, Jurgen Piek, Michael Halaska, Dimitrios Haidopoulos, Ignacio Zapardiel, Jacek P Grabowski, Vesna Kesic, Rainer Kimmig, David Cibula, Eric Lambaudie, Rene Verheijen, Ranjit Manchanda
INTRODUCTION: Advanced minimal access surgical training is an important component of training in gynecological oncology (GO). Europe-wide data on this topic are lacking. We present data on availability and trainee experience of advanced laparoscopic surgical (ALS) and robotic surgical (RS) training in GO across Europe. METHOD: A prospective web-based anonymized survey of European GO trainees was sent to the European Network of Young Gynaecological Oncologists members/trainees...
February 2017: International Journal of Gynecological Cancer
keyword
keyword
59468
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"